Tesamorelin
Tesamorelin is supplied as a stabilized GHRH(1-44) analog for growth-hormone-releasing-hormone receptor pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
Tesamorelin in research
Tesamorelin is supplied as a stabilized GHRH(1-44) analog for growth-hormone-releasing-hormone receptor pathway research.
Growth-factor, matrix, and cell-model research with careful RUO positioning.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for Tesamorelin before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
10mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Tesamorelin, a groundbreaking synthetic peptide, is at the forefront of peptide research for its promising effects on growth hormone release. This innovative peptide mimics the body's natural processes, encouraging the pituitary gland to secrete more growth hormone, which is vital for maintaining healthy body composition. Currently, tesamorelin is extensively studied for its potential to help manage abdominal fat, particularly in individuals with specific medical conditions. Researchers are excited about its ability to selectively activate growth hormone receptors, potentially leading to more targeted results with fewer side effects.
While tesamorelin is not intended for human consumption, its role in scientific studies is undeniable. The peptide's unique properties continue to offer valuable insights into metabolic processes and hormone regulation. Ongoing advancements in peptide science suggest that tesamorelin could contribute significantly to future therapeutic approaches, making it an exciting focal point for researchers and scientists worldwide.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
Tesamorelin, a GHRH analog, was studied in randomized human trials and is FDA-approved for the reduction of excess abdominal fat in HIV-associated lipodystrophy.
Preclinical work characterized GHRH-receptor activity and downstream growth-hormone-axis signaling.
Tesamorelin is discussed in fitness and anti-aging communities for body-composition interest. That is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
FDA-approved as a prescription medicine (Egrifta) for a specific indication. BioRegen supplies tesamorelin reference material strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about Tesamorelin
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010. https://doi.org/10.1210/jc.2010-0490
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. https://doi.org/10.1002/dta.3183